Other neurodegenerative conditions II

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is an autosomal-dominant neurodegenerative disease caused by mutations in the proteinase inhibitor 12 gene (PI12; SERPINI1), located on chromosome 3q26 [1]. The PI12 gene encodes the protein neuroserpin, a protein of 54–60 kDa that is expressed predominantly by neurons of the central and peripheral nervous system. Neuroserpin is a serine protease inhibitor that inhibits tissue-type plasminogen activator. Mutations in the PI12 gene lead to the formation of neuroserpin intracytoplasmic inclusion bodies (IBs), called Collins bodies, within neurons [1–3]. Accumulation of polymers composed of the mutant neuroserpin protein in IBs seems to lead to a gain of a toxic function by the mutant neuroserpin; however, loss of the normal function of neuroserpin may also contribute to the pathology, with these two mechanisms acting together to lead to the progression of the disease and neurodegeneration. In patients with FENIB, neuroserpin IBs may be found in the brain and the spinal cord. They may be also found outside the central nervous system in neurons of the dorsal root ganglion but not in cells of other organ systems [1–6]. Clinical phenotypes The onset of clinical signs and symptoms of FENIB may be highly variable depending on the specific mutation [1–8]. Patients carrying a mutation that causes high instability of neuroserpin have an earlier onset of the disease, more severe clinical manifestations, a shorter life expectancy and numerous IBs when compared with patients with a more stable mutant form of neuroserpin. The disease, which occurs equally in males and females, may present with progressive myoclonus epilepsy, focal or generalized seizures, dysarthria, tremors and dementia. Affected individuals consistently demonstrate deficits in areas associated with frontal-lobe processes. The course of the disease can be quite long, exceeding 10 years in some cases. Prior to the onset of neurological signs, mutation carriers have almost intact cognition, with the exception of restricted attention, concentration and oral fluency [8].

Original languageEnglish (US)
Title of host publicationNeuropathology of Neurodegenerative Diseases: A Practical Guide
PublisherCambridge University Press
Pages259-262
Number of pages4
ISBN (Print)9781107588660, 9781107674202
DOIs
StatePublished - Jan 1 2014

Fingerprint

Inclusion Bodies
Mutation
Neurons
Seizures
Central Nervous System
Progressive Myoclonic Epilepsy
neuroserpin
Dysarthria
Serine Proteinase Inhibitors
Poisons
Chromosomes, Human, Pair 1
Peripheral Nervous System
Spinal Ganglia
Frontal Lobe
Tremor
Tissue Plasminogen Activator
Mutant Proteins
Life Expectancy
Neurodegenerative Diseases
Cognition

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vidal, R., & Ghetti, B. (2014). Other neurodegenerative conditions II. In Neuropathology of Neurodegenerative Diseases: A Practical Guide (pp. 259-262). Cambridge University Press. https://doi.org/10.1017/CBO9781107588660.014

Other neurodegenerative conditions II. / Vidal, Ruben; Ghetti, Bernardino.

Neuropathology of Neurodegenerative Diseases: A Practical Guide. Cambridge University Press, 2014. p. 259-262.

Research output: Chapter in Book/Report/Conference proceedingChapter

Vidal, R & Ghetti, B 2014, Other neurodegenerative conditions II. in Neuropathology of Neurodegenerative Diseases: A Practical Guide. Cambridge University Press, pp. 259-262. https://doi.org/10.1017/CBO9781107588660.014
Vidal R, Ghetti B. Other neurodegenerative conditions II. In Neuropathology of Neurodegenerative Diseases: A Practical Guide. Cambridge University Press. 2014. p. 259-262 https://doi.org/10.1017/CBO9781107588660.014
Vidal, Ruben ; Ghetti, Bernardino. / Other neurodegenerative conditions II. Neuropathology of Neurodegenerative Diseases: A Practical Guide. Cambridge University Press, 2014. pp. 259-262
@inbook{a7565316ea0b4caf80d6bc4842395ac0,
title = "Other neurodegenerative conditions II",
abstract = "Introduction Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is an autosomal-dominant neurodegenerative disease caused by mutations in the proteinase inhibitor 12 gene (PI12; SERPINI1), located on chromosome 3q26 [1]. The PI12 gene encodes the protein neuroserpin, a protein of 54–60 kDa that is expressed predominantly by neurons of the central and peripheral nervous system. Neuroserpin is a serine protease inhibitor that inhibits tissue-type plasminogen activator. Mutations in the PI12 gene lead to the formation of neuroserpin intracytoplasmic inclusion bodies (IBs), called Collins bodies, within neurons [1–3]. Accumulation of polymers composed of the mutant neuroserpin protein in IBs seems to lead to a gain of a toxic function by the mutant neuroserpin; however, loss of the normal function of neuroserpin may also contribute to the pathology, with these two mechanisms acting together to lead to the progression of the disease and neurodegeneration. In patients with FENIB, neuroserpin IBs may be found in the brain and the spinal cord. They may be also found outside the central nervous system in neurons of the dorsal root ganglion but not in cells of other organ systems [1–6]. Clinical phenotypes The onset of clinical signs and symptoms of FENIB may be highly variable depending on the specific mutation [1–8]. Patients carrying a mutation that causes high instability of neuroserpin have an earlier onset of the disease, more severe clinical manifestations, a shorter life expectancy and numerous IBs when compared with patients with a more stable mutant form of neuroserpin. The disease, which occurs equally in males and females, may present with progressive myoclonus epilepsy, focal or generalized seizures, dysarthria, tremors and dementia. Affected individuals consistently demonstrate deficits in areas associated with frontal-lobe processes. The course of the disease can be quite long, exceeding 10 years in some cases. Prior to the onset of neurological signs, mutation carriers have almost intact cognition, with the exception of restricted attention, concentration and oral fluency [8].",
author = "Ruben Vidal and Bernardino Ghetti",
year = "2014",
month = "1",
day = "1",
doi = "10.1017/CBO9781107588660.014",
language = "English (US)",
isbn = "9781107588660",
pages = "259--262",
booktitle = "Neuropathology of Neurodegenerative Diseases: A Practical Guide",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Other neurodegenerative conditions II

AU - Vidal, Ruben

AU - Ghetti, Bernardino

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Introduction Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is an autosomal-dominant neurodegenerative disease caused by mutations in the proteinase inhibitor 12 gene (PI12; SERPINI1), located on chromosome 3q26 [1]. The PI12 gene encodes the protein neuroserpin, a protein of 54–60 kDa that is expressed predominantly by neurons of the central and peripheral nervous system. Neuroserpin is a serine protease inhibitor that inhibits tissue-type plasminogen activator. Mutations in the PI12 gene lead to the formation of neuroserpin intracytoplasmic inclusion bodies (IBs), called Collins bodies, within neurons [1–3]. Accumulation of polymers composed of the mutant neuroserpin protein in IBs seems to lead to a gain of a toxic function by the mutant neuroserpin; however, loss of the normal function of neuroserpin may also contribute to the pathology, with these two mechanisms acting together to lead to the progression of the disease and neurodegeneration. In patients with FENIB, neuroserpin IBs may be found in the brain and the spinal cord. They may be also found outside the central nervous system in neurons of the dorsal root ganglion but not in cells of other organ systems [1–6]. Clinical phenotypes The onset of clinical signs and symptoms of FENIB may be highly variable depending on the specific mutation [1–8]. Patients carrying a mutation that causes high instability of neuroserpin have an earlier onset of the disease, more severe clinical manifestations, a shorter life expectancy and numerous IBs when compared with patients with a more stable mutant form of neuroserpin. The disease, which occurs equally in males and females, may present with progressive myoclonus epilepsy, focal or generalized seizures, dysarthria, tremors and dementia. Affected individuals consistently demonstrate deficits in areas associated with frontal-lobe processes. The course of the disease can be quite long, exceeding 10 years in some cases. Prior to the onset of neurological signs, mutation carriers have almost intact cognition, with the exception of restricted attention, concentration and oral fluency [8].

AB - Introduction Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is an autosomal-dominant neurodegenerative disease caused by mutations in the proteinase inhibitor 12 gene (PI12; SERPINI1), located on chromosome 3q26 [1]. The PI12 gene encodes the protein neuroserpin, a protein of 54–60 kDa that is expressed predominantly by neurons of the central and peripheral nervous system. Neuroserpin is a serine protease inhibitor that inhibits tissue-type plasminogen activator. Mutations in the PI12 gene lead to the formation of neuroserpin intracytoplasmic inclusion bodies (IBs), called Collins bodies, within neurons [1–3]. Accumulation of polymers composed of the mutant neuroserpin protein in IBs seems to lead to a gain of a toxic function by the mutant neuroserpin; however, loss of the normal function of neuroserpin may also contribute to the pathology, with these two mechanisms acting together to lead to the progression of the disease and neurodegeneration. In patients with FENIB, neuroserpin IBs may be found in the brain and the spinal cord. They may be also found outside the central nervous system in neurons of the dorsal root ganglion but not in cells of other organ systems [1–6]. Clinical phenotypes The onset of clinical signs and symptoms of FENIB may be highly variable depending on the specific mutation [1–8]. Patients carrying a mutation that causes high instability of neuroserpin have an earlier onset of the disease, more severe clinical manifestations, a shorter life expectancy and numerous IBs when compared with patients with a more stable mutant form of neuroserpin. The disease, which occurs equally in males and females, may present with progressive myoclonus epilepsy, focal or generalized seizures, dysarthria, tremors and dementia. Affected individuals consistently demonstrate deficits in areas associated with frontal-lobe processes. The course of the disease can be quite long, exceeding 10 years in some cases. Prior to the onset of neurological signs, mutation carriers have almost intact cognition, with the exception of restricted attention, concentration and oral fluency [8].

UR - http://www.scopus.com/inward/record.url?scp=84955066868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955066868&partnerID=8YFLogxK

U2 - 10.1017/CBO9781107588660.014

DO - 10.1017/CBO9781107588660.014

M3 - Chapter

AN - SCOPUS:84955066868

SN - 9781107588660

SN - 9781107674202

SP - 259

EP - 262

BT - Neuropathology of Neurodegenerative Diseases: A Practical Guide

PB - Cambridge University Press

ER -